Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 7.2% – Should You Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell 7.2% on Tuesday . The company traded as low as $0.28 and last traded at $0.29. 30,458,623 shares traded hands during trading, a decline of 56% from the average session volume of 68,841,906 shares. The stock had previously closed at $0.31.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research note on Wednesday, January 1st. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Down 7.2 %

The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. The business has a 50 day moving average of $0.24 and a 200-day moving average of $0.34. The firm has a market capitalization of $54.20 million, a P/E ratio of -0.01 and a beta of 2.02.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The business had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.